caner panel sequencing. A total of 41 EGFR mutations were detected in 37 pts, most of which occurred in tyrosine kinase domain (Ex19del, 42%; L858R, 37%). Most EGFR mutation were clonal in tissue and plasma, with a consistence of 85% in paired samples. In addition, bTMB was significantly correlated to tTMB (Pearson r = 0.75, p-value = 2.3e-12), with a consistence of 90%. Interestingly, high TMB was observed in a small fraction of patients (6%) with driver mutations, such as mutations in EGFR, ALK fusion, ERBB2 and PIK3CA. Conclusions: Deep sequencing with the pan-cancer panel can effectively detect mutations and evaluate TMB in both tissue and blood with high consistence. EGFR mutations can be clonal or subclonal in both tissue and blood. Prospective multicenter study is ongoing to determine the EGFR clonality as a predictive factor for the TKI efficacy in NSCLC (TRACELib-NSCLC).
caner panel sequencing. A total of 41 EGFR mutations were detected in 37 pts, most of which occurred in tyrosine kinase domain (Ex19del, 42%; L858R, 37%). Most EGFR mutation were clonal in tissue and plasma, with a consistence of 85% in paired samples. In addition, bTMB was significantly correlated to tTMB (Pearson r = 0.75, p-value = 2.3e-12), with a consistence of 90%. Interestingly, high TMB was observed in a small fraction of patients (6%) with driver mutations, such as mutations in EGFR, ALK fusion, ERBB2 and PIK3CA. Conclusions: Deep sequencing with the pan-cancer panel can effectively detect mutations and evaluate TMB in both tissue and blood with high consistence. EGFR mutations can be clonal or subclonal in both tissue and blood. Prospective multicenter study is ongoing to determine the EGFR clonality as a predictive factor for the TKI efficacy in NSCLC (TRACELib-NSCLC Background: Lung cancer, one of the most frequent cancers worldwide has long relied on molecular testing of major biomarkers such as EGFR/ALK. Achieving superior clinical outcomes needs a comprehensive emphasis beyond contemporary EGFR and ALK. Several technologies arose in par with molecular testing for EGFR/ALK, most of them failing to comprehend beyond due to a universal skepticism among clinicians though recommended in NCCN guidelines. Methods: A total 137 lung cancer cases from NGS tested data (PositiveSelect) comprising 91 males and 46 females were investigated. EGFR, ALK positivity were used for data dichotomization to understand therapeutic utility of rare alterations beyond EGFR/ALK. Results: Upon dichotomization, 28% were identified with EGFR + ALK variants favoring direct EGFR/ALK targeted therapeutics. The remaining 72% harbored no EGFR/ALK variants descending into the category of chemotherapy in current clinical practice. Similarly, 23% harbored EGFR variants carrying the beneficial effects of EGFR TKIs and remaining 77% displayed no EGFR variants sloping towards chemotherapy. The study conquered the incompetence of targeted drug utilization on conventional diagnosis of EGFR/ALK in (EGFR) and (EGFR + ALK) negative cohorts. Based on our analysis of EGFR negative cohort, we identified clinically actionable variants in KRAS (7%), BRAF (2%), ERBB2 (1%), MET (2%) and RET (3%) expressing potential for targeted therapy excepting EGFR TKIs. Correspondingly, KRAS (6%), ERBB2 (1%), MET (1%) and RET (3%) variants were identified in EGFR + ALK negative cohort enabling the utility of targeted therapeutics apart from EGFR/ALK. Only 35% of the two negative limbs were categorized into chemotherapy which would have been entire cohort otherwise. Conclusions: The study accentuates the potential of comprehensive genomics in ascertaining the hallmarks of lung cancer beyond EGFR/ALK dichotomy also liaising between theory and utilization of broad spectrum genomic testing among medical professionals to circumvent chemotherapy. Thus, chemotherapy dependence in EGFR/ALK negative cohort could be effectively curtailed by clinicians evidencing better clinical outcomes. Legal entity responsible for the study: Positive Bioscience Funding: Has not received any funding Disclosure: All authors have declared no conflicts of interest.
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Epidermal growth factor receptor expression (EGFR) in serum as a marker of treatment response and survival in advanced squamous cell lung cancer Background: Reliable biomarkers are needed to prognostigate patients with advanced lung cancer following chemotherapy. This study evaluated the association of serum EGFR expression with disease severity and treatment response in advanced Squamous cell lung cancer. Methods: Newly diagnosed subjects with advanced Squamous cell lung cancer (stage IIIB and IV) were
